Menu
Menu
Decoded is the podcast hosted by Dr. Jurgi Camblong— Founder and CEO of SOPHiA GENETICS, molecular biologist, and global leader and pioneer of data-driven medicine.
In each episode, he connects with world-class scientists, clinicians, innovators, and policymakers to uncover how data, technology, and clinical expertise converge to transform care.
From accelerating cancer diagnostics to transforming the understanding of rare and inherited disorders, Decoded goes beyond the buzz to reveal how innovation translates into real outcomes for patients worldwide.
With a sharp focus on multimodal data, AI in healthcare, and global equal access to patient care, Decoded goes beyond theory to decode what’s working—and what it takes to scale innovation that truly improves lives.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
